Cell Biotech쎌바이오텍

Cell Biotech is a small, profitable probiotics maker with a low valuation, but its earnings have been uneven and its drug pipeline is still in early clinical testing.

Cell Biotech (049960) is a KOSDAQ probiotics company with a market value of about ₩140.9B at ₩14,990 a share. On trailing twelve-month figures to H1 2026 it had revenue of ₩60.4B, operating income of ₩10.1B, net income of ₩16.8B, and cash of ₩27.8B with no borrowings. The data does not say what drove net income to exceed operating income.

What stands out

• Revenue grew 6.4% in 2025 to ₩53.1B after falling 7.2% in 2024, and operating margin recovered from 4.1% in 2023 to 14.9% in 2025.
• 2025 net income of ₩10.1B was below 2024's ₩15.1B, and the filings in the data do not explain the swing.
• The stock trades at 8.4 times earnings and 1.0 times book, with a 4% dividend yield; the data includes a DCF model with a base value of ₩21,993, but that is a model output, not an analyst target.
• The share price sits in the upper part of its 52-week range (₩11,350 to ₩18,500) and rose 25.4% over one year, but was roughly flat over one and three months.
• Foreign ownership has stayed at 4.2% over the last 60 days, and over the past 20 days retail investors were net sellers while institutions were net buyers.

What to watch

• The next quarterly or annual results and filings; the data lists H1 2026 results (filed 14 August) as the latest, with no upcoming date given.
• Progress of the colorectal cancer treatment in its Phase 1 trial, which is the main drug development item named in the data.
• Whether revenue and operating margin hold up, since 2025 net income fell even as operating income rose, and the reasons are not in the data.